Abstract
Different strategies for treatment and prevention of Alzheimer’s disease (AD) are currently under investigation, including passive immunization with anti-amyloid β (anti-Aβ) monoclonal antibodies (mAbs). Here, we investigate the therapeutic potential of a novel type of Aβ-targeting agent based on an affibody molecule with fundamentally different properties to mAbs. We generated a therapeutic candidate, denoted Z
SYM73
-albumin-binding domain (ABD; 16.8 kDa), by genetic linkage of the dimeric Z
SYM73
affibody for sequestering of monomeric Aβ-peptides and an ABD for extension of its
in vivo
half-life. Amyloid precursor protein (APP)/PS1 transgenic AD mice were administered with Z
SYM73
-ABD, followed by behavioral examination and immunohistochemistry. Results demonstrated rescued cognitive functions and significantly lower amyloid burden in the treated animals compared to controls. No toxicological symptoms or immunology-related side-effects were observed. To our knowledge, this is the first reported
in vivo
investigation of a systemically delivered scaffold protein against monomeric Aβ, demonstrating a therapeutic potential for prevention of AD.